Furthermore, G. lucidum (0.125–0.5 mg/mL) was reported to inhibit prostate cancer-dependent angiogenesis by modulating MAPK and Akt signaling in PC-3 cells [30]. This evidence concerns the gene AKT1 and prostate carcinoma.